NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 52 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 2.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,241 | -95.5% | 3,029 | -89.1% | 0.00% | – |
Q2 2023 | $72,151 | +42.6% | 27,911 | +125.1% | 0.00% | – |
Q1 2023 | $50,600 | -13.2% | 12,402 | +6.9% | 0.00% | – |
Q4 2022 | $58,262 | -61.4% | 11,606 | 0.0% | 0.00% | – |
Q3 2022 | $151,000 | +10.2% | 11,606 | +8.8% | 0.00% | – |
Q2 2022 | $137,000 | -14.4% | 10,666 | +1.4% | 0.00% | – |
Q1 2022 | $160,000 | -14.0% | 10,518 | 0.0% | 0.00% | – |
Q4 2021 | $186,000 | -15.8% | 10,518 | 0.0% | 0.00% | – |
Q3 2021 | $221,000 | +154.0% | 10,518 | +136.1% | 0.00% | – |
Q2 2021 | $87,000 | +8.8% | 4,455 | +62.5% | 0.00% | – |
Q1 2021 | $80,000 | -7.0% | 2,742 | -3.8% | 0.00% | – |
Q4 2020 | $86,000 | +91.1% | 2,850 | 0.0% | 0.00% | – |
Q3 2020 | $45,000 | -40.0% | 2,850 | -24.9% | 0.00% | – |
Q2 2020 | $75,000 | +53.1% | 3,794 | +1.2% | 0.00% | – |
Q1 2020 | $49,000 | -46.7% | 3,749 | -25.1% | 0.00% | – |
Q4 2019 | $92,000 | +557.1% | 5,006 | +400.6% | 0.00% | – |
Q3 2019 | $14,000 | -6.7% | 1,000 | 0.0% | 0.00% | – |
Q2 2019 | $15,000 | – | 1,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 18,136,735 | $232,513,000 | 49.48% |
Ponoi II Management, LLC | 1,298,908 | $16,652,000 | 45.25% |
Ponoi Management, LLC | 1,298,908 | $16,652,000 | 26.29% |
Euclidean Capital LLC | 746,674 | $9,572,000 | 8.14% |
StepStone Group LP | 1,573,357 | $20,170,000 | 2.16% |
First Light Asset Management, LLC | 1,135,884 | $14,562,000 | 1.69% |
Lexington Partners L.P. | 110,428 | $1,416,000 | 0.73% |
Rubric Capital Management LP | 797,588 | $10,225,000 | 0.54% |
Boxer Capital, LLC | 500,000 | $6,410,000 | 0.41% |
DAFNA Capital Management LLC | 107,653 | $1,380,000 | 0.38% |